ATTD 2011 Year Book

The traditional agents for controlling the levels of glucose in the blood remain important therapies but they have their downside from the point of view of tolerability and side effects. Moreover, they appear not to be able to counter the natural history deterioration of the disease in terms of the onset of diabetic-related complications. <p>Recent years have seen an influx of new treatment therapies and technologies aimed at achieving better glycaemic control for diabetic patients such as liraglutide (Novo Nordisk) and saxagliptin (BMS/Astra-Zeneca) and insulin pumps, away from the more traditional therapies used (classic insulin therapy, oral hypoglycaemics).</p> <p>This book outlines these new technologies/treatments by collating the best journal articles published in the last year, and providing expert analysis on each one.</p> <p>Advanced Technologies and Treatment for Diabetes 3E brings together and critically analyses the last year’s most important articles published in the world’s leading medical journals on this topic. Chapters are focused on the most current hot topic areas such as: new methods of insulin delivery; internet and IT use in treatment of diabetes; bariatric surgery & diabetes; and immunotherapy for type 1 diabetes. </p> <p> Each chapter includes abstracts of the published articles, scientific conclusions made, as well as annotations and a comments and analysis section from the relevant chapter editor, each of which being a well-known expert in the field.</p> <p>All researchers in the fields of diabetes, endocrinology and metabolism will find this book extremely useful, as will diabetes technology developers, and specialist endocrinologists involved with the care of diabetic patients.</p>